Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.

Santoro, Armando; Tursz, T; Mouridsen, Henning T.; Verweij, Jaap; Steward, William P.; Somers, R.; Buesa, J. M.; Casali, Paolo; Spooner, D.; Rankin, Elaine M.

doi:10.1200/jco.1995.13.7.1537

Cited by 480 publications

(281 citation statements)

References 15 publications

Supporting

Mentioning

272

Contrasting

Unclassified

Order By: Relevance

“…In rare diseases such as soft-tissue sarcomas, patient selection may give variations in the reported response rates. Thus, to understand the low response rate, the known prognostic factors for response were compared between the present study and two other large trials of our group (Pinedo et al 1984;Santoro et al, 1995). Neither variation in the proportion of liver metastases nor the median age fully explained the observed difference in response rates.…”

Section: Trea_tmet Compliancementioning

confidence: 77%

“…In those studies. no regimen has demonstrated any advantage in terms of response rate as well as progression-free and overall sun, ixal compared x-ith single-agent doxorubicin 75 mg m-' given even 3 weeks (Verxeij et al 1995: Santoro et al 1995 (Bramxell et al 1983: Bull et al 1985. In a randomized study comparing doxorubicin and epirubicin both at a dose of 75 mg m-'2 no difference in survival and duration of response was found.…”

mentioning

confidence: 99%

See 1 more Smart Citation

High-dose epirubicin is not an alternative to standard-dose doxorubicin in the treatment of advanced soft tissue sarcomas. A study of the EORTC soft tissue and bone sarcoma group

Nielsen

Dombernowsky²,

Mouridsen³

et al. 1998

Br J Cancer

Self Cite

View full text Add to dashboard Cite

The activity and toxicity of single-agent standard-dose doxorubicin were compared with that of two schedules of high-dose epirubicin. A total of 334 chemonaive patients with histologically confirmed advanced soft-tissue sarcomas received (A) doxorubicin 75 mg m(-2) on day 1 (112 patients), (B) epirubicin 150 mg m(-2) on day 1 (111 patients) or (C) epirubicin 50 mg m(-2) day(-1) on days 1, 2 and 3 (111 patients); all given as bolus injection at 3-week intervals. A median of four treatment cycles was given. Median age was 52 years (19-70 years) and performance score 1 (0-2). Of 314 evaluable patients, 45 (14%) had an objective tumour response (eight complete response, 35 partial response). There were no differences among the three groups. Median time to progression for groups A, B and C was 16, 14 and 12 weeks, and median survival 45, 47 and 45 weeks respectively. Neither progression-free (P = 0.93) nor overall survival (P = 0.89) differed among the three groups. After the first cycle of therapy, two patients died of infection and one owing to cardiovascular disease, all on epirubicin. Both dose schedules of epirubicin were more myelotoxic than doxorubicin. Cardiotoxicity (> or = grade 3) occurred in 1%, 0% and 2% respectively. Regardless of the schedule, high-dose epirubicin is not a preferred alternative to standard-dose doxorubicin in the treatment of patients with advanced soft-tissue sarcomas.

show abstract

Section: Trea_tmet Compliancementioning

confidence: 77%

mentioning

confidence: 99%

High-dose epirubicin is not an alternative to standard-dose doxorubicin in the treatment of advanced soft tissue sarcomas. A study of the EORTC soft tissue and bone sarcoma group

Nielsen

Dombernowsky²,

Mouridsen³

et al. 1998

Br J Cancer

Self Cite

View full text Add to dashboard Cite

show abstract

“…This schedule was poorly tolerated, which contrasts with the toxicity of single-agent DXR administered at 75 mg m À2 every 3 weeks (Borden et al, 1990;Santoro et al, 1995). In three first-line studies conducted with a combination of gemcitabine followed by DXR in patients with different tumour types, projected dose intensities were 10 -25 mg m À2 week À1 for DXR and 600 -833 mg m À2 week À1 for gemcitabine.…”

Section: Discussionmentioning

confidence: 99%

Phase I/II trial of doxorubicin and fixed dose-rate infusion gemcitabine in advanced soft tissue sarcomas: a GEIS study

et al. 2006

View full text Add to dashboard Cite

The aim of the study was to determine the dose-limiting toxicity and maximum tolerated dose of a first-line combination of doxorubicin and gemcitabine in adult patients with advanced soft tissue sarcomas and to explore its activity and toxicity, and the presence of possible interactions between these agents. Patients with measurable disease were initially treated with doxorubicin 60 mg m À2 by i.v. bolus on day 1 followed by gemcitabine at 800 mg m À2 over 80 min on days 1 and 8, every 21 days. Concentrations of gemcitabine and 2 0 ,2 0 -difluorodeoxyuridine in plasma, and gemcitabine triphosphate levels in peripheral blood mononuclear cells were determined during 8 h after the start of gemcitabine infusion. Myelosuppression and stomatitis were limiting toxicities, and the initial dose level was applied for the Phase II trial, where grade 3 -4 granulocytopenia occurred in 70% of patients, grade 3 stomatitis in 46% and febrile neutropenia in 20%. Objective activity in 36 patients was 22% (95% CI: 9 -35%), and a 50% remission rate was noted in leiomyosarcomas. Administration of doxorubicin preceding gemcitabine significantly reduced the synthesis of gemcitabine triphosphate. Clinical activity, similar to that of single-agent doxorubicin, and the toxicity encountered do not justify further studies with this schedule of administration.

show abstract

“…After 6 cycles of doxorubicin (DXR) (60 mg/m 2 , on day 1 of the 21‐day cycle), a standard cytotoxic agent of soft tissue sarcoma,10, 11 a good partial response was observed, and careful observation without chemotherapy was continued for 3 months (Figure 2). Ifosfamide (IFM) administered at 1.8 mg/m 2 on days 1–3 of the 21‐day cycle was selected as a third‐line chemotherapeutic agent because it is a standard cytotoxic agent for the treatment of soft tissue sarcoma,11, 12 and CHOP (cyclophosphamide, vincristine, doxorubicin, prednisolone), which is a standard regimen for malignant lymphoma,13, 14 was selected as a fourth‐line chemotherapy treatment.…”

Section: Case Reportmentioning

confidence: 99%

Follicular dendritic cell sarcoma treated with a variety of chemotherapy

Sasaki

Izumi

Yokoyama

et al. 2016

Hematological Oncology

View full text Add to dashboard Cite

Follicular dendritic cell sarcoma (FDCS) is a very rare malignant tumor derived from follicular dendritic cells. Radical resection is the standard therapy for patients with local disease, but an optimal chemotherapy regimen has not been determined for unresectable disease. We report our experience of an FDCS patient with multiorgan involvement. In the present case, disease was only located in the pancreas initially and radical resection was performed. Multiple metastasis developed after the treatment and several factors that indicated a poor prognosis were observed. The present case had a very poor prognostic disease but survived for a long time with a good performance status because of the multiple chemotherapy regimens, which follow therapeutic strategies for malignant lymphoma and soft tissue sarcoma. As far as we know, this is the first study reporting the indication of bendamustine for FDCS patients.

show abstract

Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.

Cited by 480 publications

References 15 publications

High-dose epirubicin is not an alternative to standard-dose doxorubicin in the treatment of advanced soft tissue sarcomas. A study of the EORTC soft tissue and bone sarcoma group

High-dose epirubicin is not an alternative to standard-dose doxorubicin in the treatment of advanced soft tissue sarcomas. A study of the EORTC soft tissue and bone sarcoma group

Phase I/II trial of doxorubicin and fixed dose-rate infusion gemcitabine in advanced soft tissue sarcomas: a GEIS study

Follicular dendritic cell sarcoma treated with a variety of chemotherapy

Contact Info

Product

Resources

About